milestone pharmaceuticals is a biotechnology company located in 6100 royalmount ave, montreal, qc, canada.
Company profile
Ticker
MIST
Exchange
Website
CEO
Joseph G. Oliveto
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
MIST stock data
Latest filings (excl ownership)
8-K
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
28 Mar 24
8-K
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
4 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
28 Feb 24
8-K
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT
26 Feb 24
8-K
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
26 Dec 23
8-K
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
13 Nov 23
8-K
Company Overview CONFIDENTIAL Atrial Fibrillation Program Update November 2023
13 Nov 23
Latest ownership filings
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
GOLDMAN SACHS GROUP INC
9 Feb 24
SC 13G/A
INTEGRATED CORE STRATEGIES (US) LLC
29 Jan 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13D
Alta Fundamental Advisers LLC
9 Nov 23
4
Robert James Wills
9 Jun 23
4
MICHAEL JOHN TOMSICEK
9 Jun 23
4
Richard C Pasternak
9 Jun 23
4
Debra K. Liebert
9 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.88 mm | 9.88 mm | 9.88 mm | 9.88 mm | 9.88 mm | 9.88 mm |
Cash burn (monthly) | 7.57 mm | 2.28 mm | 5.12 mm | 5.09 mm | 4.05 mm | 4.12 mm |
Cash used (since last report) | 45.12 mm | 13.61 mm | 30.51 mm | 30.32 mm | 24.16 mm | 24.58 mm |
Cash remaining | -35.24 mm | -3.73 mm | -20.63 mm | -20.44 mm | -14.28 mm | -14.70 mm |
Runway (months of cash) | -4.7 | -1.6 | -4.0 | -4.0 | -3.5 | -3.6 |
Institutional ownership, Q3 2023
48.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 41 |
Opened positions | 2 |
Closed positions | 11 |
Increased positions | 9 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 57.86 bn |
Total shares | 26.01 mm |
Total puts | 3.80 k |
Total calls | 1.40 k |
Total put/call ratio | 2.7 |
Largest owners | Shares | Value |
---|---|---|
RTW Investments | 3.26 mm | $10.09 bn |
BLK Blackrock | 2.78 mm | $8.62 bn |
GS Goldman Sachs | 2.56 mm | $7.93 bn |
VR Adviser | 2.21 mm | $6.85 bn |
Venrock Healthcare Capital Partners III | 2.21 mm | $0.00 |
Integrated Core Strategies | 2.20 mm | $0.00 |
Millennium Management | 1.70 mm | $5.26 bn |
Fonds De Solidarite Des Travailleurs Du Quebec | 1.39 mm | $9.30 mm |
Bleichroeder | 1.33 mm | $4.11 bn |
Alta Fundamental Advisers | 1.18 mm | $3.65 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Jun 23 | Pasternak Richard C | Stock Option Common Shares | Grant | Acquire A | No | No | 3.86 | 30,000 | 115.80 k | 30,000 |
7 Jun 23 | Wills Robert James | Stock Option Common Shares | Grant | Acquire A | No | No | 3.86 | 30,000 | 115.80 k | 30,000 |
7 Jun 23 | Tomsicek Michael John | Stock Option Common Shares | Grant | Acquire A | No | No | 3.86 | 30,000 | 115.80 k | 30,000 |
7 Jun 23 | Liebert Debra K. | Stock Option Common Shares | Grant | Acquire A | No | No | 3.86 | 30,000 | 115.80 k | 30,000 |
7 Jun 23 | Fischer Seth H. Z. | Stock Option Common Shares | Grant | Acquire A | No | No | 3.86 | 30,000 | 115.80 k | 30,000 |
News
HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
22 Mar 24
Milestone Pharmaceuticals: Q4 Earnings Insights
21 Mar 24
Milestone Pharmaceuticals Q4 GAAP EPS $(0.32) Misses $(0.31) Estimate; Cash Balance Of $66M Expected To Provide Cash Runway Into 2026
21 Mar 24
Piper Sandler Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $5
5 Mar 24
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
29 Feb 24
Press releases
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
21 Mar 24
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
29 Feb 24
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
28 Feb 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Milestone Pharmaceuticals Inc.- MIST
22 Jan 24
MILESTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Milestone Pharmaceuticals Inc. on Behalf of Milestone Stockholders and Encourages Investors to Contact the Firm
18 Jan 24